This article was originally published in The Gray Sheet
Executive SummaryAgreement with Bayer Diagnostics allowing German firm to develop and distribute in vitro diagnostic tests based on Luminex' xMAP multi-analyte technology includes a multi-year deal for developing a new cellular analyzer. For the license agreement, Bayer will pay Luminex a one-time fee along with royalties once the tests are commercialized. Bayer will develop and sell the new flow cytometry analyzer for monitoring immunological status and blood disease, while Luminex will manufacture the product...
You may also be interested in...
Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.
Several newly repurposed drugs, including a Bayer antimalarial, have shown potential benefits against the new coronavirus, promoting China to add several to its latest revised treatment guidelines.
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.